UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.
Eisai Co., Ltd. and Biogen Inc. announced that the humanized amyloid-beta (Abeta monoclonal antibody “Leqembi” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the… read more.
Treatment with ubrogepant at the first sign of migraine onset appears to help prevent acute symptoms from developing. Researchers reported their findings on August 28 in Neurology. Author… read more.
Jazz Pharmaceuticals plc announced top-line results from the Phase III open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex/Epidyolex globally)… read more.
Amneal Pharmaceuticals, Inc., announced that the FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). Crexont is a novel, oral formulation… read more.
A new analysis of data from a large study of women’s health shows no link between a history of migraine and the risk of developing Parkinson’s disease (PD)…. read more.
People with multiple sclerosis (MS) do not appear to be at an increased risk of relapse after COVID-19 vaccination, researchers reported on August 14, 2024 in Neurology. “People… read more.
Inspire Medical Systems, In a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced the… read more.
Public health interventions that tackle dementia risk factors could yield as much as £4bn in savings in England by reducing dementia rates and helping people to live longer… read more.
Indivior has discontinued sales and marketing for its schizophrenia drug Perseris. This last decision, prompted by increased payor management impacts, is expected to make the product financially unviable… read more.
A large retrospective analysis of the cognitive effects of various antidiabetic treatments has disclosed that the risks of dementia and Alzheimer’s disease (AD) were significantly lower in patients… read more.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s subcutaneous version of Ocrevus (ocrelizumab subcutaneous ) to treat patients with relapsing and primary progressive… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
